Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Saturday, August 16, 2008

MS drug (FTY720) may work against viral infection: study

MS drug may work against viral infection: study

By Will Dunham
Wed Aug 13, 5:58 PM ET

WASHINGTON (Reuters) - A drug that Novartis AG is testing in people with multiple sclerosis also has the potential to treat certain viral infections, perhaps including the AIDS virus, U.S. researchers said on Wednesday.

Low doses of the drug FTY720, also called fingolimod, given to mice once a day for three days eliminated an infection by a virus that can cause meningitis, an inflammation of the membranes surrounding the brain and spinal cord.


» Read More


-

Positive Interim Analysis On Phase III Trial Of Dirucotide (MBP8298)

BioMS Medical Announces Positive Interim Analysis On Phase III Trial Of Dirucotide (MBP8298) For Multiple Sclerosis

Medical News Today - Article Date: 14 Aug 2008 - 1:00 PDT

BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that the independent Drug Safety Monitoring Board (DSMB) for the MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy and safety and has recommended that the trial continue to completion. MAESTRO-01 is the pivotal phase II/III Canadian and European study of dirucotide (MBP8298) in patients with secondary progressive MS.

The interim analysis included patients from the first 200 to complete MAESTRO-01 and assessed the likelihood of the study reaching its primary endpoint at the end of the trial in MS patients with the target HLA-DR2 and/or HLA-DR4 immune response genes. The DSMB analysis also included a scheduled review of safety information.

» Read More

.

World-Class MS Information At The Touch Of A Button

contributed by Gerson G in South Florida

World-Class MS Information At The Touch Of A Button

People affected by the debilitating neurological condition multiple sclerosis (MS) now have world-class information at their fingertips thanks to a UK first by the MS Society.

The charity, which is the largest of its kind supporting people affected by MS, has created an online library of the thousands of books, journals, papers and magazines that it has in its collection, searchable from anywhere with an internet connection.

» Read More

If you want to leave a comment to this article, you need to return-to this page

============================================

Thursday, August 14, 2008

High-dose cyclophosphamide shows promise for aggressive Multiple Sclerosis

Contributed by Trent S., in Miami

Medical Exchange.com

Source: Reuters
Date: 13 August 2008

High-dose cyclophosphamide, aimed at immune system ablation, is a safe and well-tolerated treatment for aggressive multiple sclerosis that can markedly reduce disease activity and disability, according to the results of a small, open-label trial.

In an earlier study of 13 patients with severe refractory multiple sclerosis, treatment with high-dose cyclophosphamide followed by granulocyte colony-stimulating factor often stabilized or improved disability. The current study investigated the safety and efficacy of this treatment further by examining clinical and radiologic features not previously studied and by including a longer follow-up period.

» Read More


If you want to leave a comment to this article, you need to return-to - this page

============================================

Wednesday, August 13, 2008

MS Friends - a peer support helpline


MSFriends is offering the first 24/7 telephone peer support helpline, staffed with people who have Multiple Sclerosis, a lifeline that is immediate. Call our toll free helpline at 1-866-msfriends (1-866-673-7436)
Or visit online at: www.msfriends.org

```````````````````````````````````````````````````````````````````````

The OMEGAS and Multiple Sclerosis

Obtained from the ingenious: Julie Stachowiak, Ph.D. - About.com Multiple Sclerosis Guide [ms.guide@about.com]

Omega-3 Fatty Acids and Multiple Sclerosis
Most people have heard of omega-3 essential fatty acids for heart health.
For those of us with multiple sclerosis (MS), our ears perk up when we hear
about omega-3 fatty acids also contributing to "brain health." There are even
some books and experts that claim that omega-3s can reverse our MS disease
progression and lessen our MS symptoms. So, what is the deal?

Read the full article:
Omega-3 Fatty Acids and Multiple Sclerosis: Can "Fish Oils" Help People with MS?

==============================================================================

Omega-6 Essential Fatty Acids and Multiple Sclerosis
There is great controversy surrounding omega-6 fatty acids, as most people get too
much in relation to their omega-3 fatty acid intake. However, there is some indication
that people with MS do not process it as well, leading to lower levels than in people
without MS.

Some experts argue that it would be good for people with MS to add more dietary sources
of omega-6 to their diets. Others argue that the evidence is just not there, and it should be
avoided because of potential negative health consequences.

Read the full article:
Omega-6 Essential Fatty Acids and Multiple Sclerosis: Are Omega-6 EFAs Harmful or Helpful for People with MS?

```````````````````````````````

About SF-1019 for Multiple Sclerosis

Paula of Utah asked me what it is that Alan Osmond has been chatting about, concerning a medication that he has been using (evidently in research trials).
My Thanks to Paula for her inquiry

For Paula and all else, here's the scoop:

SF-1019, as a Biological Response Modifier, may point the way for the future development and refinement of many promising innovative and cutting-edge therapeutics.

A small number of patients in the Secondary Progressive and Chronic stages of Multiple Sclerosis (MS) have also benefited from being treated with SF1019.

SF-1019 is the platform technology of Argyll Biotechnologies. It was developed from extensive research into Biological Response Modifiers (BRMs) undertaken at: Mississippi State University; St George's, University of London (formerly St George's Hospital Medical School); Ohio University; and Methodist Hospital. The first group of BRMs was designated as Immune Cell Potentiating Factors (ICPF) and has been extensively evaluated in a number of veterinary treatments, including animal studies relating to human disease. This collaborative approach brought the thorough and unbiased scrutiny of the scientific and medical community upon the related research and particularly SF-1019. In our opinion, these data collectively support the conclusion that SF-1019, as a BRM, may point the way for the future development and refinement of many promising innovative and cutting-edge therapeutics.

» Read More


If you want to leave a comment to this article, you need to return-to (or remain on) - this page

============================================

Tuesday, August 12, 2008

MRI marker of inflammatory activity in the brain?

2008 Aug 1. [Epub ahead of print]

Perivascular spaces--MRI marker of inflammatory activity in the brain?

Wuerfel J, Haertle M, Waiczies H, Tysiak E, Bechmann I, Wernecke KD, Zipp F, Paul F.


The Virchow-Robin spaces (VRS), perivascular compartments surrounding small blood vessels as they penetrate the brain parenchyma, are increasingly recognized for their role in leucocyte trafficking as well as for their potential to modulate immune responses.

In the present study, we investigated VRS numbers and volumes in different brain regions in 45 multiple sclerosis patients and 30 healthy controls of similar age and gender distribution, applying three different MRI sequence modalities (T(2)-weighted, T(1)-weighted and FLAIR). VRS were detected in comparable numbers in both multiple sclerosis patients and healthy individuals, indicating that perivascular compartments present on MRI are not a unique feature of multiple sclerosis.

» Read More


If you want to leave a comment to this article, you need to return-to (or remain on) - this page

============================================

Dose comparison trial of sustained-release Fampridine

2008 Jul 30. [Epub ahead of print]
Dose comparison trial of sustained-release fampridine in multiple sclerosis.

Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR; For the Fampridine MS-F202 Study Group.


OBJECTIVE: To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS).

METHOD: This multicenter, randomized, double-blind, placebo-controlled, parallel-group study recruited 206 participants at 24 centers in the United States and Canada. After a single-blind, 2-week placebo run-in, participants were randomly assigned to receive fampridine (10, 15, or 20 mg twice daily) or placebo for 15 weeks. The primary efficacy variable was percent change in walking speed based on the timed 25-foot walk.

» Read More


If you want to leave a comment to this article, you need to return-to (or remain on) - this page

============================================

MS Symptoms are Variable and Unpredictable

MS Symptoms are Variable and Unpredictable

No two people have exactly the same symptoms, and each person’s symptoms can change or fluctuate over time. One person might experience only one or two of the possible symptoms while another person experiences many more.

Most of these symptoms can be managed very effectively with medication, rehabilitation, and other management strategies.

============================

“Secondary” Symptoms of MS

While the primary symptoms described on this page are the direct result of damage to the myelin and nerve fibers in the CNS, the secondary symptoms are the complications that can arise as a result of the primary symptoms.

For example:

  • Bladder dysfunction can cause repeated urinary tract infections.
  • Inactivity can result in loss of muscle tone and disuse weakness (not related to demyelination), poor postural alignment and trunk control, decreased bone density (and resulting increased risk of fracture), and shallow, inefficient breathing
  • Immobility can lead to pressure sores.

While secondary symptoms can be treated, the optimal goal is to avoid them by treating the primary symptoms.

============================

source: Nat'l MS Society

============================

CNS demyelination in children

2008 Jul 30. [Epub ahead of print]
Prognostic factors after a first attack of inflammatory
CNS demyelination in children:


Neuteboom RF, Boon M, Catsman Berrevoets CE, Vles JS, Gooskens RH, Stroink H, Vermeulen RJ, Rotteveel JJ, Ketelslegers IA, Peeters E, Poll-The BT, De Rijk-Van Andel JF, Verrips A, Hintzen RQ.

OBJECTIVE: To identify clinical, radiologic, or CSF factors that predict conversion to multiple sclerosis (MS) after a first attack of inflammatory demyelination in children.

METHODS: In this nationwide retrospective multicenter study in the Netherlands, 117 children below age 16 were included. Fifty-four children presented with a monofocal clinically isolated syndrome (CIS) and 63 children with a polyfocal CIS (PCIS).

» Read More

If you want to leave a comment to this article, you need to return-to (or remain on) - this page

============================================

Monday, August 11, 2008

MS Research Studies

Just found that currently we have (323) MS Studies taking place.

To review, click here



information provided by: MS Views and Related News - Once you open the link, register for the weekly MS related e-newsletter, already being received by thousands of others




============================================

Sunday, August 10, 2008

The Handicapped Placard, Friend or Foe?

by Mandy Crest
Friday, February 08, 2008

This story was obtained from MS Central.com - Living with MS
Click HERE to see this article in it's original form and/or to leave a comment at THEIR website.
`````````````````````````````````````````````````````````````````````````````````

The handicapped placard is one of the easiest and most effective ways of managing life with a disability, yet many people with MS are hesitant to take advantage of this powerful tool.

Those of us with Relapsing/Remitting MS may feel that we are undeserving of the placard, since our disabilities are often invisible. We may be fearful of what others think of us. Will they stare at us? Will they think we are abusing the system? Some people may think that by applying for the placard they are giving in to defeat. None of these are valid reasons for not taking that step. Far from giving in, it is just one more way to maintain control of your life.

» Read More

If you want to leave a comment to this article, you need to return-to (or remain on) - this page

============================================

Games People Play

Games to help you pass some time each day.
Contributed by Susan D., in Miami


Kenai River Run (fishing)